Clinical Updates on Glioblastoma 1

A course of eight teaching modules that contains scientific reviews in e-learning format. You will have access to the latest developments in the care of patients with Neuro Oncology problems, both in the study of the disease and in the management of patients in their clinical practice.

By completing the course you will be able to obtain school credits from the National Health System.

This program has the scientific endorsement of the Spanish Neuro-Oncology Research Group (GEINO).

Dates: 11-01-2024 / 30-09-2024

Credits have been requested from the National Health System.

Nº: 09/036379-MD

Estimated teaching hours: 23h

Open 01/11/24
Lesson 1: Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter (3h)
Lesson 2: Diagnosis and management of complications from the treatment of primary central nervous system tumors in adults (5h)
Lesson 3: Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma- A phase III randomized clinical trial (2h)
 

Open 01/30/24
Lesson 4: Prognostic significance of therapy-induced myelosuppression in newly diagnosed glioblastoma (2h 30min)

Open 02/29/24
Lesson 5: Telomerase inhibition is an effective therapeutic strategy in TERT promoter-mutant glioblastoma models with low tumor volume (2h 30 min)
 

Open 03/29/24
Lesson 6: Surgical management and outcome of newly diagnosed glioblastoma without contrast enhancement (‘low grade appearance’) (2h 30 min)
 

Open 04/25/24
Lesson 7: Prognostic evaluation of re-resection for recurrent glioblastoma using the novel RANO classification for extent of resection- A report of the RANO resect group (3h)
 

Open 06/10/24
Lesson 8: Individual glioblastoma cells harbor both proliferative and invasive capabilities during tumor progression (2h 30min)